MONMOUTH JUNCTION, N.J.,
Sept. 15, 2016 /PRNewswire/ --
CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care
immunotherapy using its CytoSorb® blood purification technology to
help patients survive sepsis and other life-threatening
inflammatory conditions, announced its sponsorship of tonight's
sold-out Fifth Annual Sepsis Heroes Gala hosted by the Sepsis
Alliance at Arena NYC in New York City. Scheduled to coincide
with World Sepsis Day that is organized by the Global Sepsis
Alliance, the purpose of Sepsis Heroes is to honor people and
organizations that have made a significant contribution to sepsis
awareness and education among both the general public and
healthcare professionals.
CytoSorbents is a proud long-term sponsor of this event and
applauds the efforts of this year's honorees
including:
- Martin Doerfler, MD - Associate Chief Medical Officer at
Northwell Health and a leading advocate for sepsis awareness and
education.
- Lisa Bartlett (Davis) – Sepsis advocate who started
community awareness events in Illinois and Colorado after the death of her husband to
sepsis.
- Tom Ahrens, PhD – Nurse educator and leader in educating
nurses on sepsis best practices.
- Hillary Spangler – Sepsis survivor who has gone on to
medical school and is an advocate for sepsis education and
awareness.
- Kennedy Health System – Philadelphia-area hospital system that has
demonstrated a system-wide commitment to improving treatment and
outcomes from sepsis.
In addition, CytoSorbents commends Audrey Leishman and the
Begin Again Foundation as the first recipient of the Erin Kay
Flatley Spirit Award, given in memory of Erin Kay Flatley, a 23-year-old aspiring teacher
who died unnecessarily of sepsis after a routine surgery.
Audrey started the Begin Again Foundation in 2015 following her
survival from sepsis. The foundation provides financial support to
families struggling from their loss or disability from sepsis,
acute respiratory distress syndrome (ARDS), or toxic shock syndrome
(TSS).
Sepsis is a medical emergency caused by the overzealous immune
response to a serious infection, driven by "cytokine storm" and
destructive bacterial toxins. This causes widespread deadly
inflammation that can precipitate multiple organ failure, immune
paralysis, and death. According to the Global Sepsis
Alliance, sepsis afflicts 30 million people each year worldwide,
and kills someone every few seconds, despite the use of
antibiotics.
CytoSorbents continues to advance CytoSorb® as one of the only
safe, broad spectrum therapies to treat sepsis and other critical
illnesses where uncontrolled inflammation plays a deadly role.
Unlike other therapies, CytoSorb® attacks sepsis from multiple
angles, working to reduce cytokine storm and harmful bacterial
toxins, while helping to stabilize hemodynamics and redirect immune
cells to better fight infection. CytoSorb® is approved in the
European Union and distributed in 38 countries worldwide, but is
not yet approved in the U.S.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 38 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" or "cytokine release syndrome" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury and pancreatitis, as well as in cancer immunotherapy. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being used during and
after cardiac surgery to remove inflammatory mediators, such as
cytokines and free hemoglobin, which can lead to post-operative
complications, including multiple organ failure. CytoSorbents is in
the process of completing its REFRESH (REduction in FREe
Hemoglobin) 1 trial - a multi-center, randomized controlled study
evaluating the safety of intra-operative CytoSorb® use in a
heart-lung machine during complex cardiac surgery. In early
2017, the company plans to initiate a pivotal REFRESH 2 trial
intended to support U.S. FDA approval. CytoSorb® has been
used safely in more than 14,000 human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant and contract funding in excess of $18
million from DARPA, the U.S. Army, the U.S. Air Force, the
U.S. Department of Health and Human Services, the National
Institutes of Health (NIH), National Heart, Lung, and Blood
Institute (NHLBI), U.S. Special Operations Command (SOCOM) and
others. The Company has numerous products under development based
upon this unique blood purification technology, protected by 32
issued U.S. patents and multiple applications pending, including
CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb and others.
For more information, please visit the Company's
websites: http://www.cytosorbents.com and http://www.cytosorb.com or
follow us on Facebook and Twitter.
About the Global Sepsis Alliance
The Global Sepsis Alliance (GSA) is a non-profit organization
supporting the efforts of over 1 million caregivers in more than 70
countries as they seek to better understand and combat what many
experts believe to be the leading cause of death worldwide: sepsis.
The GSA has rallied the Global Sepsis Community to elevate public,
philanthropic and governmental awareness, understanding and support
of sepsis and to accelerate collaboration among researchers,
clinicians, associated working groups and those dedicated to
supporting them.
About the Sepsis Alliance™ and Sepsis Heroes Gala
The Sepsis Alliance is a charitable organization run by a team
of dedicated laypeople and professionals who share a strong
commitment to battling sepsis. The goal is to raise awareness
of sepsis through information and educational material so it can be
detected and treated early enough that no harm is done. The
Sepsis Heroes Gala is an award reception, being held in
New York City, designed to raise
awareness of sepsis and to recognize the unique contributions of
individuals who have committed their time and energy for the
cause. For more information, visit www.sepsisalliance.org
About World Sepsis Day
World Sepsis Day is an initiative of the Global Sepsis Alliance
(GSA) and its founding non-profit members: The World
Federation of Societies of Intensive and Critical Care Medicine,
the World Federation of Pediatric Intensive and Critical Care
Societies, the World Federation of Critical Care Nurses, the
International Sepsis Forum, and the Sepsis Alliance. The
goals of World Sepsis Day are to:
- Reduce the incidence of sepsis through effective prevention
strategies
- Increase sepsis survival rates for all population groups around
the world
- Provide better access to suitable rehabilitation services for
people everywhere
- Increase awareness and understanding of sepsis among healthcare
professionals and the general public
For more information, visit www.world-sepsis-day.org
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2016, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow us on Facebook and Twitter
Cytosorbents Contact:
Investor Relations
(732) 329-8885 ext. *825
avogel@cytosorbents.com
Public Relations Contact:
Amy
Phillips
Pascale Communications
412-327-9499
amy@pascalecommunications.com
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-sponsors-sepsis-heroes-gala-in-honor-of-world-sepsis-day-300328607.html
SOURCE CytoSorbents Corporation